Search Result

Results for "

Ponesimod

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Intermediate (1) Isotope-Labeled Compounds (2) LPL Receptor (3) Reference Standards (2)
By Research Areas:	Inflammation/Immunology (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10569

*Ponesimod* 5 Publications Verification ACT-128800	LPL Receptor	Inflammation/Immunology
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-10569S1

Ponesimod-d7 ACT-128800-d₇	Isotope-Labeled Compounds	Others
Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-Z0676

(S)-Ponesimod	Drug Intermediate	Others
(S)-Ponesimod is a drug impurity.

HY-10569R

Ponesimod (Standard) ACT-128800 (Standard)	Reference Standards LPL Receptor	Inflammation/Immunology
Ponesimod (Standard) is the analytical standard of Ponesimod. This product is intended for research and analytical applications. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-10569S

Ponesimod-d4 ACT-128800-d₄	Isotope-Labeled Compounds LPL Receptor	Others
Ponesimod-d₄ (ACT-128800-d₄) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-Z0676R

*(S)-Ponesimod* (Standard)**	Reference Standards
(Z)-5-((Z)-3-chloro-4-((S)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one (Standard) is the analytical standard of (Z)-5-((Z)-3-chloro-4-((S)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one. This product is intended for research and analytical applications.

Cat. No.	Product Name	Chemical Structure

HY-10569S1

Ponesimod-d7
Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

Ponesimod-d7

Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-10569S

Ponesimod-d4
Ponesimod-d₄ (ACT-128800-d₄) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

Ponesimod-d4

Ponesimod-d₄ (ACT-128800-d₄) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.